Companion Diagnostics Conference Boston 2027

Who sponsors ImmunoMark

Built for companies that sell to oncology R&D teams

Our London 2026 sponsors came from five kinds of company, and the Biomarkers & CDx stream adds a sixth. If yours is on this list, the agenda is built around your buyers.

Biomarker and lab services

Biomarker testing, flow cytometry and assay services for clinical trials.

Who you meet: Translational medicine and clinical biomarker leads

Preclinical models and discovery

In vivo models and antibody discovery for immuno-oncology pipelines.

Who you meet: Discovery, pharmacology and preclinical heads

Cell analysis and proteomics platforms

Instruments, reagents and platforms for immune profiling and proteomics.

Who you meet: Immune monitoring and translational science teams

Spatial biology and tissue analysis

Functional and spatial readouts from patient tissue.

Who you meet: Pathology and biomarker discovery leads

Research data and AI

Data, literature and analytics for R&D and competitive intelligence.

Who you meet: R&D strategy and data science teams

Diagnostics and CDx developers

The Biomarkers & CDx stream covers CDx development, regulatory strategy and market access.

Who you meet: Pharma CDx, regulatory and medical diagnostics leads

Stream 2: Biomarkers & Companion Diagnostics

Tell us which roles you need to meet and we will show you how the audience matches up.

Request the prospectus

East Coast CDx partnering

Why sponsor a companion diagnostics conference in Boston

ImmunoMark Boston is a companion diagnostics conference in Boston for the companies that pharma teams choose as diagnostics partners: CDx developers, IVD manufacturers, central labs, liquid biopsy companies and regulatory consultancies. The East Coast launch edition runs in June 2027, and its Stream 2 program on Biomarkers & Companion Diagnostics lists “CDx co-development, regulatory pathways, and commercialization” among its key themes.

A CDx sale is a partnering decision, made by several functions and made early. In the US, a companion diagnostic is generally expected to be approved alongside its therapy, so drug developers line up diagnostics partners well before pivotal data. A sponsor’s job is to be in the conversation while the shortlist is still open.

The lab landscape adds a second reason to be there. After a federal court vacated the FDA’s rule on laboratory-developed tests in March 2025, pharma teams are again weighing central-lab approaches against kit-based CDx strategies, program by program. Kit makers and lab service providers both have a case to make to the same buyers, and Boston puts those buyers in one place for two days.

300+industry-focused delegates expected in Boston

20 minper pre-scheduled 1:1 meeting

55+pre-scheduled 1:1s for title sponsors at London 2026

45–50%senior leadership in the prospectus seniority profile

Functions on the faculty

Who shapes a CDx partner decision, and what each function weighs

The Boston speaker panel covers the regulatory, diagnostics, pathology and precision medicine functions that sit around a co-development decision. Each one asks a diagnostics partner something different.

Function on the Boston faculty	What that function weighs in a CDx partner
Global Director of Regulatory Affairs (Precision Medicine), Gilead Sciences	Your FDA submission history, bridging study experience and readiness to file alongside the drug
Associate Director of Clinical Diagnostics, Regeneron	How your assay moves from clinical trial use to a commercial test, and on what timeline
Director, Global Regulatory Affairs, Oncology, AstraZeneca	Whether the diagnostic plan supports the oncology filing strategy in the US and other markets
Associate Principal Scientist/Associate Director (R4) – Molecular Pathology, Merck	Scoring reproducibility, tissue requirements and pathologist workflow
Scientific Director, Precision Medicine Oncology, AbbVie	Platform fit for the biomarker and the patient selection strategy

Speakers show which functions are in the room; they are not guaranteed meetings. Your 1:1s come from the full delegate list, so you can reach regulatory, precision medicine and clinical diagnostics roles at every company present. The Boston agenda names companion diagnostics developers, regulatory affairs professionals, CROs and diagnostic labs among the audiences the program is built for.

Real Boston sessions

CDx conference Boston sessions that set up your partnering meetings

Stream 2 runs from predictive biomarkers in trials to FDA approvals, value evidence and commercialization. These sessions put your buyers in a partnering frame of mind.

Day 1 · Stream 2Predictive & Prognostic Biomarkers in IO Trials
Day 1 · Stream 2Epigenetic Analysis in ctDNA
Day 1 · Stream 2Translating Biomarkers into Clinical Endpoints
Day 1 · Stream 2Panel Discussion: Commercialization of Biomarkers & CDx (moderated by Shantanu Shewale, Associate Director of Clinical Diagnostics, Regeneron, with Bianca Lauro, Principal Scientist, GPTomics)
Day 2 · Stream 2Keynote: Biomarkers in FDA Oncology Approvals
Day 2 · Stream 2Biomarkers for Early Detection & MRD
Day 2 · Stream 2Health Economics & Value of Biomarkers
Day 2 · Stream 2Future Trends in Biomarkers & CDx
Day 1 · Stream 1Translating Biomarker Data for Regulatory/FDA, Predictive and Prognostic Biomarkers in IO trials, and Neoadjuvant and Adjuvant Immunotherapy

With ctDNA and MRD on both days, this doubles as a liquid biopsy conference in Boston for companies whose tests are moving from monitoring toward patient selection. And because the program spans biomarker evidence, regulation and reimbursement, it works as a precision medicine conference in Boston for teams that sell both assay development and clinical testing. For a current view of the tests your buyers will cite, see our list of FDA-approved companion diagnostics.

How meetings work

Running CDx partnering meetings at a precision medicine summit in 2027

Pre-scheduled meetings are the center of a CDx sponsorship. Here is how to plan them for a partnering audience.

Pick a package that includes meetingsHeadline, Platinum and Gold include pre-scheduled 1:1s. The Exclusive 1:1 Meetings packages give 3, 5, 7 or 10 meetings with no booth or talk.
Shortlist from the delegate profilesThe full list arrives about 10 days before the event. Sort by function: regulatory affairs, clinical diagnostics, precision medicine, molecular pathology, business development.
Flag priority programs on the wishlistMark the indications and companies where a diagnostics decision is still open, so those requests stand out.
Bring one question per meetingTwenty minutes covers one biomarker, one indication and one decision. Bring your regulatory status, analytical performance and lab capacity for that case.
Use the panel and the receptionThe Day 1 commercialization panel runs just before the drinks reception, the right moment to pick up conversations about launch and access.

Estimate what a set of CDx partnering meetings is worth to your pipeline.

Run the ROI calculator

Package fit

Which packages fit CDx developers, IVD makers, central labs and consultancies

At a partnering-led diagnostics conference, the right package is the one that books the most qualified meetings for where you are in the relationship.

Best fit

Exclusive 1:1 Meetings

Meetings without the overhead, for regulatory consultancies, central labs and CDx business development teams who win work across a table.

3, 5, 7 or 10 pre-arranged 20-minute meetings
2–4 delegate passes, plus drinks reception passes
Wishlist and delegate list with contact details
Logo and company description in the brochure and on the webpage

Platinum (Stream 2)

For CDx developers and IVD makers with a co-development story to tell on Day 1, ahead of the commercialization panel.

30-minute Day 1 talk plus Q&A in Stream 2
10 pre-scheduled 1:1 meetings
10 x 6 ft booth
8 delegate + 8 client passes
Final delegate list a week before the event

Gold (Stream 2)

A Day 2 talk on the morning that opens with the FDA oncology approvals keynote and includes health economics.

30-minute Day 2 pre-lunch talk plus Q&A
6 pre-scheduled 1:1 meetings
10 x 6 ft booth
6 delegate + 6 client passes
Half-page brochure advertisement

Package details are on the Boston sponsorship opportunities page, and the exclusive two-stream position is on the Boston headline sponsor page. If your offer is closer to assays and platforms, see the Boston biomarker conference page; for IO services, the Boston immuno-oncology conference page. Comparing editions? The San Diego companion diagnostics conference page covers the February edition, and the London companion diagnostics conference page covers IVDR and MHRA conversations.

Tell us your target functions and we will suggest a meeting package.

Request the prospectus

Sponsorship ROI calculator

What could Boston 2027 be worth to your team?

Pick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.

1. Choose a package

Sponsorship packages

Exclusive 1:1 meeting packages

2. Your numbers

Average first-year deal value

Year-one value of a new pharma or biotech customer

Extra conversations at the event

Booth visits, networking and questions after your talk

Become a real opportunity

Share of conversations worth a proposal

Opportunities you usually win

Your typical close rate

Your total event budget

Sponsorship plus travel and team costs

Estimated return

expected first-year revenue for every $1 of your event budget

Pre-scheduled 1:1 meetings

Qualified conversations

New opportunities

Cost per conversation

Pipeline created

Expected revenue won

Get pricing and the prospectus for this package

Talk to our team

Estimates only, based on the numbers you enter. Meetings and inclusions from the Boston 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.

Email me this estimate

We will send your numbers to your inbox, ready to share with your team. Our sponsorship team gets a copy so they can answer questions.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

We are a central lab, not a kit manufacturer. Is this the right event for us?

Yes. The Boston agenda names CROs and diagnostic labs supporting biomarker assay development, patient stratification and regulatory submissions among its target audiences. Stream 2 covers the whole path from predictive biomarkers in trials to FDA approvals and commercialization, and 1:1 meetings let you reach the teams that decide how trial testing is run.

Will FDA and regulatory topics be covered?

Day 2 of Stream 2 opens with Keynote: Biomarkers in FDA Oncology Approvals, and Day 1 of Stream 1 includes Translating Biomarker Data for Regulatory/FDA, Predictive and Prognostic Biomarkers in IO trials, and Neoadjuvant and Adjuvant Immunotherapy. The speaker faculty includes Gilead Sciences' Global Director of Regulatory Affairs (Precision Medicine).

Is there liquid biopsy content?

Yes. Stream 2 includes Epigenetic Analysis in ctDNA on Day 1 and Biomarkers for Early Detection & MRD on Day 2, so liquid biopsy companies can use the event to reach precision medicine and clinical diagnostics teams.

Can a regulatory consultancy take meetings without a booth or talk?

Yes. The Exclusive 1:1 Meetings packages give 3, 5, 7 or 10 pre-arranged 20-minute meetings with delegate passes, drinks reception passes, the wishlist feature and the delegate list, with no booth or speaking commitment. Speaking slots come with Headline, Platinum, Gold and Silver, each of which includes exhibition space.

How does Boston differ from the San Diego and London CDx editions?

Boston (June 2027) is the US East Coast launch edition. San Diego (10–11 February 2027) is the West Coast launch edition. London (3–4 March 2027) is the 2nd annual edition, where European regulation such as IVDR and MHRA is part of the conversation. Packages and the meeting model are the same at every edition.

Companion Diagnostics Conference Boston: Meet CDx Partners 1:1

Get the prospectus and package availability